The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for metastatic colorectal cancer patients.
 
Yuki Matsubara
No Relationships to Disclose
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Takatsugu Ogata
No Relationships to Disclose
 
Taiko Nakazawa
No Relationships to Disclose
 
Kyoko Kato
No Relationships to Disclose
 
Kazuki Nozawa
No Relationships to Disclose
 
Yukiya Narita
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
 
Kazunori Honda
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca; Sysmex
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masashi Ando
No Relationships to Disclose
 
Masahiro Tajika
Speakers' Bureau - EA Pharma; Olympus
Research Funding - EA Pharma
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst)